Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804130 | 0.84 | ALDH1A1 (0.39) | TAS1R3TAS1R1ALDH1A1HPGDKMT2A | |
| SCHEMBL803601 | 0.82 | ALDH1A1 (0.44) | TAS1R3TAS1R1ALDH1A1HPGDKMT2A | |
| SCHEMBL15896801 | 0.79 | ALDH1A1 (0.38) | TAS1R3TAS1R1ALDH1A1HPGDKMT2A | |
| Bromide SCHEMBL786345 | 0.78 | ALDH1A1 (0.37) | TAS1R3TAS1R1ALDH1A1HPGDKMT2A | |
| SCHEMBL15896809 | 0.78 | KMT2A (0.39) | TAS1R3TAS1R1ALDH1A1HPGDKMT2A | |
| Bromide SCHEMBL786195 | 0.77 | KMT2A (0.40) | TAS1R3TAS1R1ALDH1A1HPGDKMT2A | |
| SCHEMBL13186818 | 0.71 | ALDH1A1 (0.38) | TAS1R3TAS1R1ALDH1A1HPGDKMT2A | |
| SCHEMBL803897 | 0.70 | EDNRA (0.46) | TAS1R3TAS1R1HPGDKMT2AMEN1 | |
| SCHEMBL5720890 | 0.69 | KMT2A (0.48) | TAS1R3TAS1R1ALDH1A1HPGDKMT2A | |
| SCHEMBL803624 | 0.68 | EDNRA (0.55) | TAS1R3TAS1R1HPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785655-B2 | Ionic liquid solvents | DUBLIN CITY UNIVERSITY (IE) | 2014-07-22 | — | — | US | disclosed |
| US-20120071661-A1 | Ionic Liquid Solvents | DUBLIN CITY UNIVERSITY (IE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071661-A1 | Ionic Liquid Solvents | EBP, PAICS, HACD3 | TAS1R3 3512/4885TAS1R1 3477/4885ALDH1A1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.